Analysts Set ADC Therapeutics SA (NYSE:ADCT) Price Target at $6.33

Shares of ADC Therapeutics SA (NYSE:ADCT) have been given a consensus rating of “Hold” by the six research firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $7.50.

ADCT has been the topic of several recent analyst reports. Guggenheim initiated coverage on shares of ADC Therapeutics in a research note on Thursday, March 28th. They set a “buy” rating and a $11.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $9.00 price target on shares of ADC Therapeutics in a report on Wednesday, March 6th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $8.00 price target on shares of ADC Therapeutics in a report on Thursday, March 14th.

ADC Therapeutics Stock Down 1.1 %

Shares of NYSE:ADCT opened at $4.44 on Thursday. The company’s fifty day moving average is $4.25 and its two-hundred day moving average is $2.20. ADC Therapeutics has a 12-month low of $0.36 and a 12-month high of $6.04. The company has a market cap of $366.43 million, a P/E ratio of -1.52 and a beta of 1.73.

Institutional Investors Weigh In On ADC Therapeutics

Large investors have recently bought and sold shares of the business. Advisor Group Holdings Inc. boosted its holdings in ADC Therapeutics by 1,270.5% in the first quarter. Advisor Group Holdings Inc. now owns 3,248 shares of the company’s stock worth $47,000 after purchasing an additional 3,011 shares in the last quarter. Quantbot Technologies LP bought a new stake in ADC Therapeutics in the second quarter worth $38,000. Tower Research Capital LLC TRC boosted its holdings in ADC Therapeutics by 1,253.3% in the third quarter. Tower Research Capital LLC TRC now owns 9,473 shares of the company’s stock worth $46,000 after purchasing an additional 8,773 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new position in ADC Therapeutics during the 3rd quarter worth $56,000. Finally, Prospera Financial Services Inc acquired a new position in ADC Therapeutics during the 1st quarter worth $25,000. 41.10% of the stock is currently owned by institutional investors.

About ADC Therapeutics

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.